Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04251221 · ClinicalTrials.gov registry record · Early Phase 1
Measuring the Neuroimmune Response to Alcohol
A Early Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 14
- Enrollment target
NCT04251221 is a Early Phase 1 study that has completed, run by Yale University. The registered enrollment target is 14 participants.
The verdict
NCT04251221, a Early Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study uses positron emission tomography imaging of the 18-kDa translocator protein to measure the brain's immune response to alcohol.
Interventions
- DRUG Oral Alcohol Challenge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-06-20 |
| Est. Completion | 2021-11-20 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04251221
The ClinicalTrials.gov registry entry for NCT04251221 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oral Alcohol Challenge is the first listed.
NCT04251221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04251221 about?
NCT04251221 is a clinical study titled "Measuring the Neuroimmune Response to Alcohol". This study uses positron emission tomography imaging of the 18-kDa translocator protein to measure the brain's immune response to alcohol.
What is the current status of trial NCT04251221?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 14 participants. The study started on 2019-06-20. Estimated completion is 2021-11-20.
What interventions are being tested in trial NCT04251221?
The interventions under investigation include: Oral Alcohol Challenge (DRUG).
Who is sponsoring clinical trial NCT04251221?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.